OTCMKTS:POLXF - Polydex Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.93 +0.12 (+14.81 %) (As of 01/23/2019 06:04 AM ET)Previous Close$0.81Today's Range$0.8650 - $0.9352-Week Range$0.81 - $1.36Volume300 shsAverage Volume308 shsMarket Capitalization$3.14 millionP/E Ratio9.00Dividend YieldN/ABeta-0.26 ProfileDiscussionChartEarningsFinancialsHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Polydex Pharmaceuticals Limited, through its subsidiaries, manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry worldwide. It also develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market. The company primarily offers dextran and derivative products, including Iron Dextran, a derivative of dextran that is injected into pigs at birth as a treatment for anemia; and dextran sulphate, a specialty chemical derivative of dextran used in biotechnology applications and the pharmaceutical industry. It also provides ferric hydroxide and hydrogenated dextran to Sparhawk Laboratories Inc. In addition, the company develops Ushercell, a high molecular weight cellulose sulphate for topical vaginal use primarily in the prevention and transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies; and Usherdex 4, a low molecular weight dextran product for the treatment of cystic fibrosis, a genetic disease. Polydex Pharmaceuticals Limited sells its iron dextran primarily to independent distributors and wholesalers primarily in Europe, the Far East, South America, and Canada; and Dextran Sulphate to independent distributors or companies in the United States and Europe for analytical applications. The company was formerly known as Polydex Chemicals Limited and changed its name to Polydex Pharmaceuticals Limited in March 1984. Polydex Pharmaceuticals Limited was founded in 1966 and is based in Toronto, Canada. Receive POLXF News and Ratings via Email Sign-up to receive the latest news and ratings for POLXF and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Industrial inorganic chemicals Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:POLXF Previous Symbol CUSIPN/A Webwww.polydex.com Phone416-755-2231Debt Debt-to-Equity Ratio0.04 Current Ratio3.97 Quick Ratio2.97Price-To-Earnings Trailing P/E Ratio9.00 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.28 million Price / Sales0.60 Cash Flow$0.2372 per share Price / Cash Flow3.92 Book Value$1.70 per share Price / Book0.55Profitability EPS (Most Recent Fiscal Year)N/A Net Income$450,000.00 Net Margins5.46% Return on Equity5.04% Return on Assets3.93%Miscellaneous Employees23 Outstanding Shares3,380,000Market Cap$3.14 million OptionableNot Optionable Polydex Pharmaceuticals (OTCMKTS:POLXF) Frequently Asked Questions What is Polydex Pharmaceuticals' stock symbol? Polydex Pharmaceuticals trades on the OTCMKTS under the ticker symbol "POLXF." When is Polydex Pharmaceuticals' next earnings date? Polydex Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 7th 2019. View Earnings Estimates for Polydex Pharmaceuticals. Has Polydex Pharmaceuticals been receiving favorable news coverage? Media headlines about POLXF stock have trended positive recently, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Polydex Pharmaceuticals earned a news impact score of 2.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 8.0 out of 10, indicating that recent news coverage is very likely to have an effect on the company's share price in the near future. Who are some of Polydex Pharmaceuticals' key competitors? Some companies that are related to Polydex Pharmaceuticals include Linde (LIN), Air Products & Chemicals (APD), JSR CORP/ADR (JSCPY), Minerals Technologies (MTX), Kronos Worldwide (KRO), Valhi (VHI), Tronox (TROX), Luxfer (LXFR), Venator Materials (VNTR), NL Industries (NL), LSB Industries (LXU), Hydrogenics (HYGS) and Praxair (PX). Who are Polydex Pharmaceuticals' key executives? Polydex Pharmaceuticals' management team includes the folowing people: Mr. George G. Usher, Chairman, CEO & Pres (Age 60)Mr. John Alfred Luce, CFO & Principal Accounting Officer (Age 72)Ms. Sharon L. Wardlaw, COO, Treasurer & Sec. (Age 66) How do I buy shares of Polydex Pharmaceuticals? Shares of POLXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Polydex Pharmaceuticals' stock price today? One share of POLXF stock can currently be purchased for approximately $0.93. How big of a company is Polydex Pharmaceuticals? Polydex Pharmaceuticals has a market capitalization of $3.14 million and generates $5.28 million in revenue each year. Polydex Pharmaceuticals employs 23 workers across the globe. What is Polydex Pharmaceuticals' official website? The official website for Polydex Pharmaceuticals is http://www.polydex.com. How can I contact Polydex Pharmaceuticals? Polydex Pharmaceuticals' mailing address is 421 COMSTOCK ROAD, TORONTO A6, M1L 2H5. The company can be reached via phone at 416-755-2231 or via email at [email protected] MarketBeat Community Rating for Polydex Pharmaceuticals (OTCMKTS POLXF)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 59 (Vote Outperform)Underperform Votes: 44 (Vote Underperform)Total Votes: 103MarketBeat's community ratings are surveys of what our community members think about Polydex Pharmaceuticals and other stocks. Vote "Outperform" if you believe POLXF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe POLXF will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/23/2019 by MarketBeat.com StaffFeatured Article: What is the quiet period?